SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies

  • By

  • Pragna Patel

  • Jessica K. Sprinkles

  • Andrew Godoshian

  • Marcus Siddall

  • Timothy M. Uyeki

  • Henry Walke

  • Joseph Miller

  • November 18, 2026

Share

Clinical Scorecard: Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies

At a Glance

Category

Detail

Condition

Concurrent SARS-CoV-2 and influenza infection (coinfection)

Key Mechanisms

Coinfection is identified by positive tests for both SARS-CoV-2 and influenza; the article notes prior evidence linking coinfection with higher risk of severe outcomes.

Target Population

People tested for SARS-CoV-2 and influenza A and B at participating US pharmacies from September 1, 2023, through May 31, 2025.

Care Setting

Community pharmacies participating in the Increasing Community Access to Testing, Treatment, and Response program.

Key Highlights

  • Among 817,834 people tested, 665 (0.1%) tested positive for both viruses; estimated coinfection prevalence was 0.081% (95% CI, 0.075%-0.087%).

  • Coinfection prevalence was highest among children younger than 18 years (0.145%); adjusted odds were higher than among adults aged 18 to 64 years (OR, 1.93; 95% CI, 1.42-2.57).

  • Among 665 people with coinfection, 26 (3.9%) received COVID-19 treatment and 29 (4.4%) received influenza treatment; none received treatment for both infections.

  • Among 144 symptomatic people with coinfection who reported health histories, 63.9% reported no comorbidities; cough, headache, and congestion were the most common symptoms.

  • The authors note that pharmacy clinicians might consider prompt COVID-19 and/or influenza therapy for symptomatic people vulnerable to severe outcomes.

Guideline-Based Recommendations

Diagnosis

  • The study defined coinfection as positive tests for both SARS-CoV-2 and influenza virus.

  • Testing used a multiplex SARS-CoV-2/influenza A and B assay or a laboratory-based nucleic acid amplification test.

Management

  • For symptomatic people vulnerable to severe outcomes, pharmacy clinicians might consider prompt COVID-19 and/or influenza therapy during respiratory season, according to the article.

  • The article reports that antiviral medications may lower the risk of severe COVID-19 and certain influenza complications.

Monitoring & Follow-up

  • The study assessed antiviral dispensing, but available data on symptoms, comorbidities, severity, treatment, and outcomes were limited by nonresponse and prescriptions received elsewhere.

Risks

  • Prior investigations cited by the article linked SARS-CoV-2 and influenza coinfection with higher risk of severe outcomes.

  • Coinfection odds were lower among people aged 65 years or older than among those aged 18 to 64 years (OR, 0.69; 95% CI, 0.53-0.89).

Patient & Prescribing Data

The cohort included 817,834 pharmacy-tested people across 50 states, the District of Columbia, and Puerto Rico; median age was 40 years, and 61.2% were female.

Of 665 people with coinfection, 26 received COVID-19 treatment and 29 received influenza treatment; no one received treatment for both. Among coinfected adults aged 18 to 64 years with at least one comorbidity, 19 of 42 (45.2%) received each type of treatment.

Clinical Best Practices

  • Use multiplex testing to identify concurrent SARS-CoV-2 and influenza infection in community pharmacy settings.

  • Consider prompt COVID-19 and/or influenza therapy for symptomatic people vulnerable to severe outcomes, as stated by the article.

  • Interpret treatment and symptom findings in light of incomplete survey responses and prescriptions that may have been obtained elsewhere.

Related Resources & Content

  1. JAMA Network Open, 2026 -- SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies

  2. Centers for Disease Control and Prevention, 2026 -- Clinical Guidance for Hospitalized and Non-Hospitalized Patients When SARS-CoV-2, RSV, and Influenza Viruses are Co-Circulating

  3. Centers for Disease Control and Prevention, 2026 -- Influenza Antiviral Medications: Summary for Clinicians

  4. Centers for Disease Control and Prevention, 2026 -- Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV

  5. Infectious Diseases Society of America, 2026 -- IDSA Guidelines on the Treatment and Management of Patients with COVID-19

  6. the pathologist — Shifts in Influenza Activity 2018 to 2023

  7. MDSpire News — COVID-19 & Flu Vaccines Study: Comparable Safety

  8. the pathologist — Flu Season in the Time of COVID-19

  9. mdspire news — Same-Day COVID, Flu Vaccination Appears Safe

  10. Clinical Guidance for Hospitalized and Non-Hospitalized Patients When SARS-CoV-2, RSV, and Influenza Viruses are Co-Circulating

  11. Influenza Antiviral Medications: Summary for Clinicians

  12. Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV

  13. IDSA Guidelines on the Treatment and Management of Patients with COVID-19

  14. SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies | Infectious Diseases | JAMA Network Open | JAMA Network

  15. Clinical impact of coinfection with SARS-CoV-2, influenza virus, and respiratory syncytial virus among adults: a multicenter retrospective cohort study [2021–2025]

  16. Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023

Original Source(s)

Related Content